Skip to main content
  • The PlexABMR test measures the risk of rejection in which B-cells play a major role by producing antibodies against the transplanted organ.
  • Antibody-mediated rejection (ABMR) is a less common form of rejection compared with cellular rejection, however, it has been linked to accelerated graft loss.
  • Antibody-mediated rejection can accompany cellular rejection and requires different drugs than cellular rejection. It is not easily distinguished from acute cellular rejection.
  • ABMR often accompanies acute cellular rejection and other types of injury on a biopsy.
  • Information about the risk of ABMR can facilitate early preventive measures, drug selection, treatment, and improve graft health as well as longevity.
  • This test is under development. If you are interested in learning more, please subscribe to our updates.
  • For details on the clinical trials conducted, please check this link.

The PlexABMR test measures the risk of Antibody-mediated rejection in which B-cells play a major role by producing antibodies against the transplanted organ.

About

Plexision develops cellular biomarkers for personalized diagnosis and drug development in solid organ transplantation and immunological disorders. We also pioneer in R&D projects centered on integrating biomarker targets in all phases of drug development, from preclinical to post-marketing. Plexision’s technology can be adapted to

  • - Assess disease risk for several immunological disorders.
  • - Predict the success of a drug for a specific patient.
  • - Develop dosing recommendations for new immunological drugs.

Our state-of-the-art laboratory is CLIA-certified and located in Pittsburgh, PA.

Contact